Foley Partner Recognized at 2019 Intellectual Property Owners Association (IPO) Annual Meeting
26 September 2019
In recognition of exceptional service, Partner Eley Thompson and fellow members of the IPO Litigation Committee received the Outstanding Committee of the Year Award at IPO’s 47th Annual Meeting in Washington, DC. The award was presented during the keynote session on Thursday, September 26th.
Each year, the IPO Annual Meeting brings together IP professionals from corporations, law firms, government, academia, and service providers from around the world to discuss industry strategies, trends, and best practices.
For more information about IPO and the Annual Meeting, please visit the IPO website.
Each year, the IPO Annual Meeting brings together IP professionals from corporations, law firms, government, academia, and service providers from around the world to discuss industry strategies, trends, and best practices.
For more information about IPO and the Annual Meeting, please visit the IPO website.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”